Lieve Mj Naesens

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2271277/publications.pdf

Version: 2024-02-01

242	9,559	41344	56724
papers	citations	49 h-index	83 g-index

261	261	261	7965
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Overcome Double Trouble: Baloxavir Marboxil Suppresses Influenza Thereby Mitigating Secondary Invasive Pulmonary Aspergillosis. Journal of Fungi (Basel, Switzerland), 2022, 8, 1.	3.5	12
2	Synthesis and structureâ€“activity relationship of L â€methionineâ€coupled 1,3,4â€thiadiazole derivatives withÂactivity against influenza virus. Chemical Biology and Drug Design, 2022, 99, 398-415.	3.2	3
3	In Vitro Characterization of the Carbohydrate-Binding Agents HHA, GNA, and UDA as Inhibitors of Influenza A and B Virus Replication. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	8
4	New spirothiazolidinone derivatives: Synthesis and antiviral evaluation. Phosphorus, Sulfur and Silicon and the Related Elements, 2021, 196, 294-299.	1.6	4
5	The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways. PLoS Pathogens, 2021, 17, e1009500.	4.7	91
6	Helicobacter pylori Xanthineâ€“Guanineâ€“Hypoxanthine Phosphoribosyltransferaseâ€”A Putative Target for Drug Discovery against Gastrointestinal Tract Infections. Journal of Medicinal Chemistry, 2021, 64, 5710-5729.	6.4	4
7	Betulonic Acid Derivatives Interfering with Human Coronavirus 229E Replication via the nsp15 Endoribonuclease. Journal of Medicinal Chemistry, 2021, 64, 5632-5644.	6.4	26
8	Favipiravir Does Not Inhibit Chikungunya Virus Replication in Mosquito Cells and Aedes aegypti Mosquitoes. Microorganisms, 2021, 9, 944.	3.6	4
9	Design, synthesis and anti-influenza virus activity of furan-substituted spirothiazolidinones. Bioorganic Chemistry, 2021, 112, 104958.	4.1	10
10	Facile synthesis, antimicrobial and antiviral evaluation of novel substituted phenyl 1,3-thiazolidin-4-one sulfonyl derivatives. Bioorganic Chemistry, 2021, 114, 105153.	4.1	4
11	Exploration of the 2,3-dihydroisoindole pharmacophore for inhibition of the influenza virus PA endonuclease. Bioorganic Chemistry, 2021, 116, 105388.	4.1	3
12	Early oseltamivir reduces risk for influenza-associated aspergillosis in a double-hit murine model. Virulence, 2021, 12, 2493-2508.	4.4	20
13	A broad influenza virus inhibitor acting via IMP dehydrogenase and in synergism with ribavirin. Antiviral Research, 2021, 196, 105208.	4.1	4
14	Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones. Bioorganic and Medicinal Chemistry, 2020, 28, 115130.	3.0	20
15	Design and synthesis of novel Imidazo[2,1-b]thiazole derivatives as potent antiviral and antimycobacterial agents. Bioorganic Chemistry, 2020, 95, 103496.	4.1	40
16	Discovery of dihydroxyindole-2-carboxylic acid derivatives as dual allosteric HIV-1 Integrase and Reverse Transcriptase associated Ribonuclease H inhibitors. Antiviral Research, 2020, 174, 104671.	4.1	14
17	Synthesis of Antiviral Perfluoroalkyl Derivatives of Teicoplanin and Vancomycin. ChemMedChem, 2020, 15, 1661-1671.	3.2	15
18	Bicyclic Î±-Iminophosphonates as High Affinity Imidazoline I₂ Receptor Ligands for Alzheimerâ€™s Disease. Journal of Medicinal Chemistry, 2020, 63, 3610-3633.	6.4	17

#	Article	IF	Citations
19	Anti-influenza virus activity of benzo[d]thiazoles that target heat shock protein 90. Bioorganic Chemistry, 2020, 98, 103733.	4.1	16
20	N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide interaction. European Journal of Medicinal Chemistry, 2020, 194, 112223.	5.5	11
21	Reprogramming of the Antibacterial Drug Vancomycin Results in Potent Antiviral Agents Devoid of Antibacterial Activity. Pharmaceuticals, 2020, 13, 139.	3.8	17
22	Synthesis and Biological Evaluation of Novel (thio)semicarbazone-Based Benzimidazoles as Antiviral Agents against Human Respiratory Viruses. Molecules, 2020, 25, 1487.	3.8	44
23	Synthesis and biological evaluation of substituted phenyl azetidine-2-one sulphonyl derivatives as potential antimicrobial and antiviral agents. Bioorganic Chemistry, 2020, 104, 104320.	4.1	10
24	Design, synthesis, antitubercular and antiviral properties of new spirocyclic indole derivatives. Monatshefte FÃ¼r Chemie, 2019, 150, 1533-1544.	1.8	22
25	Novel Nâ€(1â€thiaâ€4â€azaspiro[4.5]decanâ€4â€yl)carboxamide derivatives as potent and selective influenza virus fusion inhibitors. Archiv Der Pharmazie, 2019, 352, e1900028.	4.1	5
26	Hemagglutinin Cleavability, Acid Stability, and Temperature Dependence Optimize Influenza B Virus for Replication in Human Airways. Journal of Virology, 2019, 94, .	3.4	32
27	Synthesis and antiâ€coronavirus activity of a series of 1â€thiaâ€4â€azaspiro[4.5]decanâ€3â€one derivatives. Archiv Der Pharmazie, 2019, 352, e1800330.	4.1	16
28	Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir). Antiviral Research, 2019, 167, 1-5.	4.1	25
29	4,4-Disubstituted N-benzylpiperidines: A Novel Class of Fusion Inhibitors of Influenza Virus H1N1 Targeting a New Binding Site in Hemagglutinin. Proceedings (mdpi), 2019, 22, .	0.2	0
30	Influenza virus entry via the GM3 ganglioside-mediated platelet-derived growth factor receptor Î² signalling pathway. Journal of General Virology, 2019, 100, 583-601.	2.9	34
31	Amino acid and peptide prodrugs of diphenylpropanones positive allosteric modulators of Î±7 nicotinic receptors with analgesic activity. European Journal of Medicinal Chemistry, 2018, 143, 157-165.	5.5	6
32	Antiviral activity and metal ion-binding properties of some 2-hydroxy-3-methoxyphenyl acylhydrazones. BioMetals, 2018, 31, 81-89.	4.1	5
33	Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion. Journal of Medicinal Chemistry, 2018, 61, 98-118.	6.4	31
34	Design of Plasmodium vivax Hypoxanthine-Guanine Phosphoribosyltransferase Inhibitors as Potential Antimalarial Therapeutics. ACS Chemical Biology, 2018, 13, 82-90.	3.4	22
35	Pyrrolidine nucleoside bisphosphonates as antituberculosis agents targeting hypoxanthine-guanine phosphoribosyltransferase. European Journal of Medicinal Chemistry, 2018, 159, 10-22.	5.5	10
36	Bis coumarinyl bis triazolothiadiazinyl ethane derivatives: Synthesis, antiviral activity evaluation, and molecular docking studies. Synthetic Communications, 2018, 48, 1494-1503.	2.1	15

#	Article	IF	Citations
37	Identification of influenza PA-Nter endonuclease inhibitors using pharmacophore- and docking-based virtual screening. Bioorganic and Medicinal Chemistry, 2018, 26, 4544-4550.	3.0	9
38	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents. European Journal of Medicinal Chemistry, 2018, 157, 1017-1030.	5.5	17
39	Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR). European Journal of Medicinal Chemistry, 2018, 155, 229-243.	5.5	19
40	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 6193-6210.	6.4	32
41	Synthesis and antiviral activity evaluation of new 4-thiazolidinones bearing an imidazo[2,1-b]thiazole moiety. Marmara Pharmaceutical Journal, 2018, 22, 237-248.	0.5	15
42	Synthesis and biological evaluation of lipophilic teicoplanin pseudoaglycon derivatives containing a substituted triazole function. Journal of Antibiotics, 2017, 70, 152-157.	2.0	21
43	Airway proteases: an emerging drug target for influenza and other respiratory virus infections. Current Opinion in Virology, 2017, 24, 16-24.	5.4	93
44	Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus. Journal of Medicinal Chemistry, 2017, 60, 3727-3738.	6.4	20
45	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus. European Journal of Medicinal Chemistry, 2017, 135, 467-478.	5.5	28
46	Synthesis and evaluation of symmetric acyclic nucleoside bisphosphonates as inhibitors of the Plasmodium falciparum, Plasmodium vivax and human 6-oxopurine phosphoribosyltransferases and the antimalarial activity of their prodrugs. Bioorganic and Medicinal Chemistry, 2017, 25, 4008-4030.	3.0	20
47	Diclofenacâ€Based Hydrazones and Spirothiazolidinones: Synthesis, Characterization, and Antimicrobial Properties. Archiv Der Pharmazie, 2017, 350, 1700010.	4.1	7
48	Metal-chelating properties and antiviral activity of some 2-hydroxyphenyl amides. Polyhedron, 2017, 129, 97-104.	2.2	5
49	Synthesis and in vitro antiviral evaluation of 4-substituted 3,4-dihydropyrimidinones. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 139-142.	2.2	27
50	Editorial overview: Antiviral strategies: Antiviral drug design: creating new ideas against old and new bugs. Current Opinion in Virology, 2017, 24, v-vii.	5.4	1
51	Synthesis and Evaluation of Asymmetric Acyclic Nucleoside Bisphosphonates as Inhibitors of Plasmodium falciparum and Human Hypoxanthineâ€“Guanineâ€“(Xanthine) Phosphoribosyltransferase. Journal of Medicinal Chemistry, 2017, 60, 7539-7554.	6.4	18
52	Chelation Motifs Affecting Metal-dependent Viral Enzymes: Nâ€²-acylhydrazone Ligands as Dual Target Inhibitors of HIV-1 Integrase and Reverse Transcriptase Ribonuclease H Domain. Frontiers in Microbiology, 2017, 8, 440.	3.5	27
53	Cidofovir is active against human papillomavirus positive and negative head and neck and cervical tumor cells by causing DNA damage as one of its working mechanisms. Oncotarget, 2016, 7, 47302-47318.	1.8	14
54	Inhibitory Effect of 2,3,5,6-Tetrafluoro-4-[4-(aryl)-1H-1,2,3-triazol-1-yl]benzenesulfonamide Derivatives on HIV Reverse Transcriptase Associated RNase H Activities. International Journal of Molecular Sciences, 2016, 17, 1371.	4.1	13

#	Article	IF	Citations
55	Resistance to the nucleotide analogue cidofovir in HPV(+) cells: a multifactorial process involving UMP/CMP kinase 1. Oncotarget, 2016, 7, 10386-10401.	1.8	6
56	Crystal structures and inhibition of Trypanosoma brucei hypoxanthineâ€“guanine phosphoribosyltransferase. Scientific Reports, 2016, 6, 35894.	3.3	15
57	Crystal Structures of Acyclic Nucleoside Phosphonates in Complex withEscherichia coliHypoxanthine Phosphoribosyltransferase. ChemistrySelect, 2016, 1, 6267-6276.	1.5	8
58	1,6-Bis[(benzyloxy)methyl]uracil derivativesâ€”Novel antivirals with activity against HIV-1 and influenza H1N1 virus. Bioorganic and Medicinal Chemistry, 2016, 24, 2476-2485.	3.0	8
59	Antiviral therapies on the horizon for influenza. Current Opinion in Pharmacology, 2016, 30, 106-115.	3.5	67
60	First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via â€˜privileged scaffoldâ€™ refining approach. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5182-5186.	2.2	33
61	The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug Design. Medicinal Research Reviews, 2016, 36, 1127-1173.	10.5	129
62	Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis. Antimicrobial Agents and Chemotherapy, 2016, 60, 6679-6691.	3.2	86
63	N-acylhydrazone inhibitors of influenza virus PA endonuclease with versatile metal binding modes. Scientific Reports, 2016, 6, 31500.	3.3	49
64	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones. Bioorganic and Medicinal Chemistry, 2016, 24, 240-246.	3.0	62
65	Novel indoleâ€“flutimide heterocycles with activity against influenza PA endonuclease and hepatitis C virus. MedChemComm, 2016, 7, 447-456.	3.4	24
66	Synthesis and Antimicrobial Evaluation of 6â€Alkylaminoâ€Nâ€phenylpyrazineâ€2â€carboxamides. Chemical Biology and Drug Design, 2015, 86, 674-681.	3.2	9
67	Synthesis and Biological Evaluation of N-Alkyl-3-(alkylamino)-pyrazine-2-carboxamides. Molecules, 2015, 20, 8687-8711.	3.8	15
68	Alkylamino derivatives of N-benzylpyrazine-2-carboxamide: synthesis and antimycobacterial evaluation. MedChemComm, 2015, 6, 1311-1317.	3.4	11
69	A versatile salicyl hydrazonic ligand and its metal complexes as antiviral agents. Journal of Inorganic Biochemistry, 2015, 150, 9-17.	3.5	46
70	Aza-acyclic Nucleoside Phosphonates Containing a Second Phosphonate Group As Inhibitors of the Human, Plasmodium falciparum and vivax 6-Oxopurine Phosphoribosyltransferases and Their Prodrugs As Antimalarial Agents. Journal of Medicinal Chemistry, 2015, 58, 827-846.	6.4	49
71	Synthesis and Structure-Activity Relationship of N-(3-Oxo-1-Thia-4-Azaspiro[4.5]Decan-4-Yl)Carboxamide Inhibitors of Influenza Virus Hemagglutinin Mediated Fusion. Phosphorus, Sulfur and Silicon and the Related Elements, 2015, 190, 1075-1087.	1.6	10
72	Ritter reaction-mediated syntheses of 2-oxaadamantan-5-amine, a novel amantadine analog. Tetrahedron Letters, 2015, 56, 1272-1275.	1.4	8

#	Article	IF	Citations
73	Synthesis and Preliminary Antiviral Activities of Piperidineâ€substituted Purines against <scp>HIV</scp> and Influenza A/H1N1 Infections. Chemical Biology and Drug Design, 2015, 86, 568-577.	3.2	17
74	An Integrated Biological Approach to Guide the Development of Metal-Chelating Inhibitors of Influenza Virus PA Endonuclease. Molecular Pharmacology, 2015, 87, 323-337.	2.3	33
75	Alpha-carboxy nucleoside phosphonates as universal nucleoside triphosphate mimics. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3475-3480.	7.1	29
76	Virtual Screening and Biological Validation of Novel Influenza Virus PA Endonuclease Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 866-871.	2.8	33
77	Synthesis of a sialic acid derivative of ristocetin aglycone as an inhibitor of influenza virus. Chemical Papers, 2015, 69, .	2.2	2
78	New polycyclic dual inhibitors of the wild type and the V27A mutant M2 channel of the influenza A virus with unexpected binding mode. European Journal of Medicinal Chemistry, 2015, 96, 318-329.	5.5	18
79	First Crystal Structures of Mycobacterium tuberculosis 6-Oxopurine Phosphoribosyltransferase: Complexes with GMP and Pyrophosphate and with Acyclic Nucleoside Phosphonates Whose Prodrugs Have Antituberculosis Activity. Journal of Medicinal Chemistry, 2015, 58, 4822-4838.	6.4	36
80	A few atoms make the difference: Synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives. European Journal of Medicinal Chemistry, 2015, 94, 73-86.	5.5	11
81	Investigation of the salicylaldehyde thiosemicarbazone scaffold for inhibition of influenza virus PA endonuclease. Journal of Biological Inorganic Chemistry, 2015, 20, 1109-1121.	2.6	44
82	Antimalarial activity of prodrugs of N-branched acyclic nucleoside phosphonate inhibitors of 6-oxopurine phosphoribosyltransferases. Bioorganic and Medicinal Chemistry, 2015, 23, 5502-5510.	3.0	29
83	Pronounced Inhibition Shift from HIV Reverse Transcriptase to Herpetic DNA Polymerases by Increasing the Flexibility of Î±-Carboxy Nucleoside Phosphonates. Journal of Medicinal Chemistry, 2015, 58, 8110-8127.	6.4	9
84	Norbornane-based nucleoside and nucleotide analogues locked in North conformation. Bioorganic and Medicinal Chemistry, 2015, 23, 184-191.	3.0	16
85	Acyclic nucleoside phosphonates containing a second phosphonate group are potent inhibitors of the 6-oxopurine phosphoribosyltransferases and have antimalarial activity. Malaria Journal, 2014, 13, P91.	2.3	0
86	Treating HHV-6 Infections. , 2014, , 311-331.		40
87	Synthesis of a cluster-forming sialylthio-d-galactose fullerene conjugate and evaluation of its interaction with influenza virus hemagglutinin and neuraminidase. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2420-2423.	2.2	28
88	Emerging Antiviral Strategies to Interfere with Influenza Virus Entry. Medicinal Research Reviews, 2014, 34, 301-339.	10.5	91
89	Metal-Chelating 2-Hydroxyphenyl Amide Pharmacophore for Inhibition of Influenza Virus Endonuclease. Molecular Pharmaceutics, 2014, 11, 304-316.	4.6	38
90	Antiretroviral activity of metal-chelating HIV-1 integrase inhibitors. European Journal of Medicinal Chemistry, 2014, 83, 594-600.	5.5	21

#	Article	IF	Citations
91	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: Synthesis and antiviral studies. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3251-3254.	2.2	23
92	Azapropellanes with Anti-Influenza A Virus Activity. ACS Medicinal Chemistry Letters, 2014, 5, 831-836.	2.8	23
93	Easily Accessible Polycyclic Amines that Inhibit the Wild-Type and Amantadine-Resistant Mutants of the M2 Channel of Influenza A Virus. Journal of Medicinal Chemistry, 2014, 57, 5738-5747.	6.4	51
94	Synthesis, Characterization and Biological Evaluation Against Influenza Virus Agonists of (N'E,N'"E)-2,2'-[[1,1'-Biphenyl]-4,4'-dihylbis(oxy)]bis (N'-arylmethyleneacetohydrazides). Letters in Organic Chemistry, 2014, 11, 168-173.	0.5	2
95	Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage. BMC Medical Genomics, 2013, 6, 18.	1.5	15
96	An intriguing and facile one-pot catalytic synthesis of N-alkylated lactams. Monatshefte FÃ¼r Chemie, 2013, 144, 515-521.	1.8	4
97	3-Azatetracyclo[5.2.1.1^{5,8}.0^{1,5}]undecane Derivatives: From Wild-Type Inhibitors of the M2 Ion Channel of Influenza A Virus to Derivatives with Potent Activity against the V27A Mutant. Journal of Medicinal Chemistry, 2013, 56, 9265-9274.	6.4	46
98	Mutational Analysis of the Binding Pockets of the Diketo Acid Inhibitor L-742,001 in the Influenza Virus PA Endonuclease. Journal of Virology, 2013, 87, 10524-10538.	3.4	67
99	Inhibition of the Escherichia coli 6-Oxopurine Phosphoribosyltransferases by Nucleoside Phosphonates: Potential for New Antibacterial Agents. Journal of Medicinal Chemistry, 2013, 56, 6967-6984.	6.4	41
100	Role of the viral hemagglutinin in the anti-influenza virus activity of newly synthesized polycyclic amine compounds. Antiviral Research, 2013, 99, 281-291.	4.1	26
101	Synthesis and Biological Evaluation of Purine 2â€²â€Fluoroâ€2â€²â€deoxyriboside ProTides as Antiâ€influenza Virus Agents. ChemMedChem, 2013, 8, 415-425.	3.2	12
102	Cidofovir treatment improves the pathology caused by the growth of human papillomavirus-positive cervical carcinoma xenografts in athymic nude mice. Cancer Letters, 2013, 329, 137-145.	7.2	11
103	Acyclic Nucleoside Phosphonates Containing a Second Phosphonate Group Are Potent Inhibitors of 6-Oxopurine Phosphoribosyltransferases and Have Antimalarial Activity. Journal of Medicinal Chemistry, 2013, 56, 2513-2526.	6.4	59
104	Evaluation of Novel Acyclic Nucleoside Phosphonates against Human and Animal Gammaherpesviruses Revealed an Altered Metabolism of Cyclic Prodrugs upon Epstein-Barr Virus Reactivation in P3HR-1 Cells. Journal of Virology, 2013, 87, 12422-12432.	3.4	16
105	Role of Human Hypoxanthine Guanine Phosphoribosyltransferase in Activation of the Antiviral Agent T-705 (Favipiravir). Molecular Pharmacology, 2013, 84, 615-629.	2.3	94
106	Intracytoplasmic Trapping of Influenza Virus by a Lipophilic Derivative of Aglycoristocetin. Journal of Virology, 2012, 86, 9416-9431.	3.4	31
107	Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives. Bioorganic and Medicinal Chemistry, 2012, 20, 7155-7159.	3.0	34
108	Synthesis of fluorescent ristocetin aglycon derivatives with remarkable antibacterial and antiviral activities. European Journal of Medicinal Chemistry, 2012, 58, 361-367.	5.5	11

#	Article	IF	Citations
109	Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7092-7096.	2.2	17
110	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds. ACS Medicinal Chemistry Letters, 2012, 3, 1065-1069.	2.8	33
111	Interaction between Mouse Adenovirus Type 1 and Cell Surface Heparan Sulfate Proteoglycans. PLoS ONE, 2012, 7, e31454.	2.5	15
112	Synthesis of Novel AZA-Analogues of Tiazofurin with 2-[5,5-bis(Hydroxymethyl)Pyrrolidin-2-yl] Framework as Sugar Mimic. Nucleosides, Nucleotides and Nucleic Acids, 2012, 31, 72-84.	1.1	8
113	Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents. Archives of Pharmacal Research, 2012, 35, 975-986.	6.3	13
114	Synthesis and biological evaluation of pyrimidine nucleoside monophosphate prodrugs targeted against influenza virus. Antiviral Research, 2012, 94, 35-43.	4.1	49
115	Synthesis of benzopolycyclic cage amines: NMDA receptor antagonist, trypanocidal and antiviral activities. Bioorganic and Medicinal Chemistry, 2012, 20, 942-948.	3.0	17
116	Synthesis and Preliminary Biologic Evaluation of 5â€Substitutedâ€2â€(4â€substituted phenyl)â€1,3â€Benzoxazoles as A Novel Class of Influenza Virus A Inhibitors. Chemical Biology and Drug Design, 2012, 79, 1018-1024.	3.2	7
117	Exploring the Size Limit of Templates for Inhibitors of the M2 Ion Channel of Influenza A Virus. Journal of Medicinal Chemistry, 2011, 54, 2646-2657.	6.4	69
118	Adefovir serum levels do not differ between responders and nonresponders. Journal of Viral Hepatitis, 2011, 18, e175-8.	2.0	1
119	Discovery of Dihydroâ€Alkyloxyâ€Benzylâ€Oxopyrimidines as Promising Antiâ€Influenza Virus Agents. Chemical Biology and Drug Design, 2011, 78, 596-602.	3.2	6
120	6-Oxopurine Phosphoribosyltransferase: A Target for the Development of Antimalarial Drugs. Current Topics in Medicinal Chemistry, 2011, 11, 2085-2102.	2.1	36
121	Synthesis and Antiviral Evaluation of Bisnoradamantane Sulfites and Related Compounds. Medicinal Chemistry, 2011, 7, 135-140.	1.5	0
122	Solid state properties of pure UC-781 and solid dispersions with polyvinylpyrrolidone (PVP K30). Journal of Pharmacy and Pharmacology, 2010, 53, 1109-1116.	2.4	14
123	Novel Inhibitors of Influenza Virus Fusion: Structure-Activity Relationship and Interaction with the Viral Hemagglutinin. Journal of Virology, 2010, 84, 4277-4288.	3.4	137
124	Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin. Bioorganic and Medicinal Chemistry, 2010, 18, 2748-2755.	3.0	29
125	Plasmodium vivax hypoxanthine-guanine phosphoribosyltransferase: A target for anti-malarial chemotherapy. Molecular and Biochemical Parasitology, 2010, 173, 165-169.	1.1	35
126	Conservation of HHV-6 DNA polymerase processivity factor sequence and predicted structure suggests it as a target for antiviral development. Antiviral Research, 2010, 86, 316-319.	4.1	2

#	Article	IF	Citations
127	Polycyclic Nâ€Benzamido Imides with Potent Activity against Vaccinia Virus. ChemMedChem, 2010, 5, 2072-2078.	3.2	12
128	Alkoxyâ€5â€nitrosopyrimidines: Useful Building Block for the Generation of Biologically Active Compounds. European Journal of Organic Chemistry, 2010, 2010, 3823-3830.	2.4	23
129	Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2713-2717.	2.2	19
130	Design and synthesis of bioactive adamantanaminoalcohols and adamantanamines. European Journal of Medicinal Chemistry, 2010, 45, 5022-5030.	5.5	31
131	Cytotoxicity of Natural Compounds Isolated from the Seeds ofGarcinia afzelii. Planta Medica, 2010, 76, 708-712.	1.3	18
132	Synthesis of Ester Prodrugs of 9-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as Anti-Poxvirus Agents. Journal of Medicinal Chemistry, 2010, 53, 6825-6837.	6.4	30
133	Anti-influenza virus activity and structureâ€“activity relationship of aglycoristocetin derivatives with cyclobutenedione carrying hydrophobic chains. Antiviral Research, 2009, 82, 89-94.	4.1	49
134	Mouse adenovirus type 1 and human adenovirus type 5 differ in endothelial cell tropism and liver targeting. Journal of Gene Medicine, 2009, 11, 119-127.	2.8	13
135	Synthesis of 1,2-annulated adamantane heterocycles: structural determination studies of a bioactive cyclic sulfite. Tetrahedron Letters, 2009, 50, 2671-2675.	1.4	11
136	Cytostatic and Antiviral Activity Evaluations of Hydroxamic Derivatives of Some Nonâ€steroidal Antiâ€inflammatory Drugs. Chemical Biology and Drug Design, 2009, 73, 328-338.	3.2	8
137	Synthesis of a pericosine analogue with a bicyclo[2.2.2]octene skeleton. Tetrahedron, 2009, 65, 8171-8175.	1.9	6
138	Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity. Bioorganic and Medicinal Chemistry, 2009, 17, 1534-1541.	3.0	44
139	Synthesis and pharmacological evaluation of (2-oxaadamant-1-yl)amines. Bioorganic and Medicinal Chemistry, 2009, 17, 3198-3206.	3.0	22
140	Inhibition of Hypoxanthine-Guanine Phosphoribosyltransferase by Acyclic Nucleoside Phosphonates: A New Class of Antimalarial Therapeutics. Journal of Medicinal Chemistry, 2009, 52, 4391-4399.	6.4	107
141	Diazo Transferâ^'Click Reaction Route to New, Lipophilic Teicoplanin and Ristocetin Aglycon Derivatives with High Antibacterial and Anti-influenza Virus Activity: An Aggregation and Receptor Binding Study. Journal of Medicinal Chemistry, 2009, 52, 6053-6061.	6.4	44
142	Clinical features and treatment of adenovirus infections. Reviews in Medical Virology, 2008, 18, 357-374.	8.3	210
143	Synthesis, cytostatic and anti-HIV evaluations of the new unsaturated acyclic C-5 pyrimidine nucleoside analogues. Bioorganic and Medicinal Chemistry, 2008, 16, 5624-5634.	3.0	59
144	Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure. Bioorganic and Medicinal Chemistry, 2008, 16, 8379-8389.	3.0	38

#	Article	IF	Citations
145	Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs. Bioorganic and Medicinal Chemistry, 2008, 16, 9925-9936.	3.0	33
146	Design and synthesis of bioactive 1,2-annulated adamantane derivatives. Organic and Biomolecular Chemistry, 2008, 6, 3177.	2.8	35
147	Characterization of a cidofovir-resistant HHV-6 mutant obtained by in vitro selection. Antiviral Research, 2008, 77, 237-240.	4.1	31
148	Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine. Biochemical Pharmacology, 2008, 76, 997-1005.	4.4	21
149	4â€²â€²-Benzoylureido-TSAO Derivatives as Potent and Selective Non-Nucleoside HCMV Inhibitors. Structureâ^'Activity Relationship and Mechanism of Antiviral Action. Journal of Medicinal Chemistry, 2008, 51, 5823-5832.	6.4	22
150	Synthesis and Absolute Configuration of Novel N,O-Psiconucleosides Using (R)-N-Phenylpantolactam as a Resolution Agent. Journal of Organic Chemistry, 2008, 73, 6657-6665.	3.2	17
151	Recovery of Humoral Immunity Is Critical for Successful Antiviral Therapy in Disseminated Mouse Adenovirus Type 1 Infection. Antimicrobial Agents and Chemotherapy, 2008, 52, 1462-1471.	3.2	18
152	Suboptimal Response to Adefovir Dipivoxil Therapy for Chronic Hepatitis B in Nucleoside-Naive Patients is not due to Pre-Existing Drug-Resistant Mutants. Antiviral Therapy, 2008, 13, 381-388.	1.0	38
153	Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. Journal of Antimicrobial Chemotherapy, 2007, 60, 1316-1330.	3.0	73
154	Ester Prodrugs of Cyclic 1-(S)- [3-Hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine:â€‰ Synthesis and Antiviral Activity. Journal of Medicinal Chemistry, 2007, 50, 5765-5772.	6.4	50
155	Î·6-(Arene)tricarbonylchromium and Manganese Complexes Linked to 2â€˜-Deoxyuridine. Organometallics, 2007, 26, 5727-5730.	2.3	13
156	Antiviral Activity of Triazine Analogues of 1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine (Cidofovir) and Related Compounds. Journal of Medicinal Chemistry, 2007, 50, 1069-1077.	6.4	79
157	Design and synthesis of bioactive adamantane spiro heterocycles. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4358-4362.	2.2	90
158	Different Mutations in the HHV-6 DNA Polymerase Gene Accounting for Resistance to Foscarnet. Antiviral Therapy, 2007, 12, 877-888.	1.0	35
159	Antiviral activity of diverse classes of broad-acting agents and natural compounds in HHV-6-infected lymphoblasts. Journal of Clinical Virology, 2006, 37, S69-S75.	3.1	55
160	In search of effective anti-HHV-6 agents. Journal of Clinical Virology, 2006, 37, S82-S86.	3.1	31
161	61: In vitro selection and characterization of human herpesvirus 6 strains resistant to foscarnet or cidofovir. Journal of Clinical Virology, 2006, 37, S113-S114.	3.1	1
162	75 Mouse models for the evaluation of antiviral and immunotherapy in the treatment of systemic adenovirus infections. International Journal of Infectious Diseases, 2006, 10, S42.	3.3	0

#	Article	IF	Citations
163	Mouse adenovirus type 1 attachment is not mediated by the coxsackie-adenovirus receptor. FEBS Letters, 2006, 580, 3937-3942.	2.8	14
164	Therapeutic Approaches to HHV-6 Infection. Perspectives in Medical Virology, 2006, 12, 291-301.	0.1	2
165	Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature, 2006, 439, 745-748.	27.8	180
166	Heterocyclic rimantadine analogues with antiviral activity. Bioorganic and Medicinal Chemistry, 2006, 14, 3341-3348.	3.0	109
167	Antiviral properties of new arylsulfone derivatives with activity against human betaherpesviruses. Antiviral Research, 2006, 72, 60-67.	4.1	30
168	Antiviral therapy for adenovirus infections. Antiviral Research, 2006, 71, 172-180.	4.1	92
169	Introduction to the Special Issue dedicated to Prof. Erik De Clercq for reaching the Professor Emeritus status at the Katholieke Universiteit Leuven. Antiviral Research, 2006, 71, 75-76.	4.1	1
170	Adjuvant Low-Dose Cidofovir Therapy for BK Polyomavirus Interstitial Nephritis in Renal Transplant Recipients. American Journal of Transplantation, 2005, 5, 1997-2004.	4.7	157
171	Quantitative analysis of human herpesvirus 6 cell tropism. Journal of Medical Virology, 2005, 75, 76-85.	5.0	84
172	Successful use of intralesional and intravenous cidofovir in association with indole-3-carbinol in an 8-year-old girl with pulmonary papillomatosis. Journal of Medical Virology, 2005, 75, 332-335.	5.0	16
173	Update on Human Herpesvirus 6 Biology, Clinical Features, and Therapy. Clinical Microbiology Reviews, 2005, 18, 217-245.	13.6	466
174	Mouse Adenovirus Type 1 Infection in SCID Mice: an Experimental Model for Antiviral Therapy of Systemic Adenovirus Infections. Antimicrobial Agents and Chemotherapy, 2005, 49, 4689-4699.	3.2	30
175	ANTIVIRAL POTENTIAL OF A NEW GENERATION OF ACYCLIC NUCLEOSIDE PHOSPHONATES, THE 6-[2-(PHOSPHONOMETHOXY)ALKOXY]-2,4-DIAMINOPYRIMIDINES. Nucleosides, Nucleotides and Nucleic Acids, 2005, 24, 331-341.	1.1	66
176	Human herpesvirus 6 DNA polymerase: enzymatic parameters, sensitivity to ganciclovir and determination of the role of the A961V mutation in HHV-6 ganciclovir resistance. Antiviral Research, 2004, 64, 17-25.	4.1	26
177	Potent, selective and cell-mediated inhibition of human herpesvirus 6 at an early stage of viral replication by the non-nucleoside compound CMV423. Biochemical Pharmacology, 2004, 67, 325-336.	4.4	69
178	Phosphonates with Antiviral Activity. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 1321-1327.	1.1	28
179	Human herpesvirus 6 infection arrests cord blood mononuclear cells in G2phase of the cell cycle. FEBS Letters, 2004, 560, 25-29.	2.8	29
180	Characterization of the Catalytic Subunit of the Human Herpesvirus 6 (HHV-6) DNA Polymerase Expressed in an In Vitro Transcription/Translation Assay. Nucleosides, Nucleotides and Nucleic Acids, 2003, 22, 999-1001.	1.1	3

#	Article	IF	Citations
181	Metabolic and Pharmacological Characteristics of the Bicyclic Nucleoside Analogues (BCNAs) as Highly Selective Inhibitors of Varicella-Zoster Virus (VZV). Nucleosides, Nucleotides and Nucleic Acids, 2003, 22, 995-997.	1.1	8
182	Study of Different Substituted Cyclic and Acyclic Benzylpronucleotides of d4T Relative to Their Hydrolytic Stability and Antiviral Activity. Nucleosides, Nucleotides and Nucleic Acids, 2003, 22, 791-795.	1.1	2
183	Specific Recognition of the Bicyclic Pyrimidine Nucleoside Analogs, a New Class of Highly Potent and Selective Inhibitors of Varicella-Zoster Virus (VZV), by the VZV-Encoded Thymidine Kinase. Molecular Pharmacology, 2002, 61, 249-254.	2.3	51
184	Intestinal Absorption Enhancement of the Ester Prodrug Tenofovir Disoproxil Fumarate through Modulation of the Biochemical Barrier by Defined Ester Mixtures. Drug Metabolism and Disposition, 2002, 30, 924-930.	3.3	86
185	Role of the Human Herpesvirus 6 U69-Encoded Kinase in the Phosphorylation of Ganciclovir. Molecular Pharmacology, 2002, 62, 714-721.	2.3	45
186	6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with Antiviral Activity. Journal of Medicinal Chemistry, 2002, 45, 1918-1929.	6.4	129
187	Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci, 2002, 4, 22-30.	1.3	90
188	2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections. Antiviral Research, 2002, 55, 413-424.	4.1	46
189	Intestinal absorption characteristics of the low solubility thiocarboxanilide UC-781. International Journal of Pharmaceutics, 2002, 234, 113-119.	5.2	24
190	Thermal characterization of the antiviral drug UC-781 and stability of its glass. Thermochimica Acta, 2001, 366, 61-69.	2.7	8
191	Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Reviews in Medical Virology, 2001, 11, 381-395.	8.3	157
192	Anti-herpesvirus activity of (1â€²S,2â€²R)-9-[[1â€²,2â€²-bis(hydroxymethyl)-cycloprop-1â€²-yl]methyl]guanine (A-5021) in vitro and in vivo. Antiviral Research, 2001, 49, 115-120.	4.1	17
193	ACYCLIC/CARBOCYCLIC GUANOSINE ANALOGUES AS ANTI-HERPESVIRUS AGENTS. Nucleosides, Nucleotides and Nucleic Acids, 2001, 20, 271-285.	1.1	60
194	In Vitro, Ex Vivo, and In Situ Intestinal Absorption Characteristics of the Antiviral Ester Prodrug Adefovir Dipivoxil. Journal of Pharmaceutical Sciences, 2000, 89, 1054-1062.	3.3	34
195	Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14. European Journal of Pharmaceutical Sciences, 2000, 10, 311-322.	4.0	187
196	Partial purification and characterization of mitochondrial DNA polymerase from Plasmodium falciparum. Parasitology International, 2000, 49, 279-288.	1.3	12
197	Evaluation of the potential of ion pair formation to improve the oral absorption of two potent antiviral compounds, AMD3100 and PMPA. International Journal of Pharmaceutics, 1999, 186, 127-136.	5.2	27
198	Inhibition of intestinal metabolism of the antiviral ester prodrug bis(POC)-PMPA by nature-identical fruit extracts as a strategy to enhance its oral absorption: an in vitro study. Pharmaceutical Research, 1999, 16, 1035-1040.	3.5	23

#	Article	IF	Citations
199	N6-cyclopropyl-PMEDAP: a novel derivative of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) with distinct metabolic, antiproliferative, and differentiation-inducing properties. Biochemical Pharmacology, 1999, 58, 311-323.	4.4	35
200	Adefovir dipivoxil. Drugs, 1999, 58, 488-489.	10.9	0
201	Inhibition of the in vitro growth of Plasmodium falciparum by acyclic nucleoside phosphonates. International Journal of Antimicrobial Agents, 1999, 12, 53-61.	2.5	26
202	Antitumor Potential of Acyclic Nucleoside Phosphonates. Nucleosides & Nucleotides, 1999, 18, 759-771.	0.5	41
203	Comparison of the disposition of ester prodrugs of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine [PMEA] in Caco-2 monolayers. Pharmaceutical Research, 1998, 15, 239-245.	3.5	10
204	Carrier mechanisms involved in the transepithelial transport of bis(POM)-PMEA and its metabolites across Caco-2 monolayers. Pharmaceutical Research, 1998, 15, 1168-1173.	3.5	22
205	Stability of UC-781, in intestinal mucosal homogenates of the rat, rabbit, and pig. Pharmaceutical Research, 1998, 15, 1799-1802.	3.5	2
206	Potent differentiation-inducing properties of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in the rat choriocarcinoma (RCHO) tumor cell model. Biochemical Pharmacology, 1998, 56, 851-859.	4.4	18
207	Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]. Journal of Medical Virology, 1998, 54, 219-225.	5.0	240
208	Selection and characterisation of murine leukaemia L1210 cells with high-level resistance to the cytostatic activity of the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine (PMEA). Biochimica Et Biophysica Acta - Molecular Cell Research, 1998, 1402, 29-38.	4.1	6
209	New antivirals â€" mechanism of action and resistance development. Current Opinion in Microbiology, 1998, 1, 535-546.	5.1	41
210	Treatment of Visna Virus Infection in Lambs with the Acyclic Nucleoside Phosphonate Analogue 9-(2-Phosphonylmethoxyethyl)Adenine (PMEA). Antiviral Chemistry and Chemotherapy, 1998, 9, 245-252.	0.6	2
211	Efficacy of the Acyclic Nucleoside Phosphonates(S)-9-(3-Fluoro-2-Phosphonylmethoxypropyl)Adenine (FPMPA) and 9-(2-Phosphonylmethoxyethyl)Adenine (PMEA) Against Feline Immunodeficiency Virus. Journal of Acquired Immune Deficiency Syndromes, 1998, 17, 120-128.	0.3	22
212	Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. Aids, 1998, 12, 1129-1138.	2.2	83
213	Antiretroviral Efficacy and Pharmacokinetics of Oral Bis(isopropyloxycarbonyloxymethyl)9-(2-Phosphonylmethoxypropyl)adenine in Mice. Antimicrobial Agents and Chemotherapy, 1998, 42, 1568-1573.	3.2	135
214	HPMPC (cidofovir), PMEA (adefovir) and Related Acyclic Nucleoside Phosphonate Analogues: A Review of their Pharmacology and Clinical Potential in the Treatment of Viral Infections. Antiviral Chemistry and Chemotherapy, 1997, 8, 1-23.	0.6	214
215	Therapeutic Potential of HPMPC (Cidofovir), PMEA (Adefovir) and Related Acyclic Nucleoside Phosphonate Analogues as Broad-Spectrum Anttviral Agents. Nucleosides & Nucleotides, 1997, 16, 983-992.	0.5	25
216	Effects of 2â€²,3â€²-dideoxycytidine and 2â€²,3â€²-dideoxycytidine 5â€²-triphosphate on phospholipid metabolism in permeabilized rat hepatocytes. Biochemical Pharmacology, 1997, 54, 713-719.	4.4	4

#	Article	IF	Citations
217	Conversion of 2â€²,3â€²-dideoxyadenosine (ddA) and 2â€²,3â€²-didehydro-2â€²,3â€²-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus. FEBS Letters, 1997, 410, 324-328.	2.8	55
218	Phosphoramidate derivatives of d4T as inhibitors of HIV: The effect of amino acid variation. Antiviral Research, 1997, 35, 195-204.	4.1	66
219	Anti-retrovirus activity and pharmacokinetics in mice of bis(POC)-PMPA, the bis(isopropyloxycarbonyloxymethyl) oral prodrug of PMPA. Antiviral Research, 1997, 34, A50.	4.1	4
220	Anti-HIV activity and metabolism of phosphoramidate derivatives of D4T-MP with variations in the amino acid moiety. Antiviral Research, 1997, 34, A54.	4.1	1
221	Transport, uptake, and metabolism of the bis(pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2). Pharmaceutical Research, 1997, 14, 492-496.	3.5	48
222	Introductory Article: Anti-infectives: Present status of HIV protease inhibitors in the control of HIV infections. Expert Opinion on Investigational Drugs, 1996, 5, 153-154.	4.1	2
223	Treatment of Adenoviral Conjunctivitis with Topical Cidofovir. Cornea, 1996, 15, 546.	1.7	34
224	Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 7295-7299.	7.1	105
225	(S)â€9â€(3â€hydroxyâ€2â€phosphonylmethoxypropyl)adenine [(S)â€HPMPA]: a purine analogue with trypanocidal activity in vitro and in vivo. Tropical Medicine and International Health, 1996, 1, 255-263.	2.3	26
226	Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6. Antiviral Research, 1995, 28, 343-357.	4.1	98
227	In vivo Antiretroviral Efficacy of Oral bis(POM)-PMEA, the bis(Pivaloyloxymethyl)prodrug of 9-(2-Phosphonylmethoxyethyl) adenine (PMEA). Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 767-770.	1.1	19
228	Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine on visna virus infection in lambs: a model for in vivo testing of candidate anti-human immunodeficiency virus drugs.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 3283-3287.	7.1	20
229	(R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy, 1995, 39, 746-749.	3.2	42
230	Antiviral Activity of Selected Nucleoside Analogues Against Human Herpes Virus Type 6. Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 567-570.	1.1	6
231	Modified Cyclodextrin Sulphates(mCDS11) have Potent Inhibitory Activity against HIV and High Oral Bioavailability. Antiviral Chemistry and Chemotherapy, 1994, 5, 155-161.	0.6	19
232	Therapeutic potential of PMEA as an antiviral drug. Reviews in Medical Virology, 1994, 4, 147-159.	8.3	57
233	Efficacy of oral 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the treatment of retrovirus and cytomegalovirus infections in mice. Journal of Medical Virology, 1993, 39, 167-172.	5.0	32
234	Metabolism and pharmacokinetics of the anti-HIV-1-specific inhibitor		

#	Article	IF	Citations
235	Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrobial Agents and Chemotherapy, 1993, 37, 332-338.	3.2	333
236	Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice. Journal of Medical Virology, 1992, 37, 67-71.	5.0	62
237	Single-dose administration of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the prophylaxis of retrovirus infection in vivo. Antiviral Research, 1991, 16, 53-64.	4.1	35
238	9-(2-phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. Aids, 1991, 5, 21-28.	2.2	209
239	Inhibitory effects of 9-(2-Phosphonylmethoxyethyl)adenine and 3â€²-azido-2â€²,3â€²-dideoxythymidine on tumor development in mice inoculated intracerebrally with moloney murine sarcoma virus. International Journal of Cancer, 1990, 45, 486-489.	5.1	30
240	Anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine (pmea)in vivo increases when it is less frequently administered. International Journal of Cancer, 1990, 46, 337-340.	5.1	51
241	9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP): A novel agent with anti-human immunodeficiency virus activity in vitro and potent anti-moloney murine sarcoma virus activity in vivo. European Journal of Clinical Microbiology and Infectious Diseases, 1989, 8, 1043-1047.	2.9	58
242	Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 332-336.	7.1	202